Catabasis Pharmaceuticals,Inc.Files An 8-K Other Events

50

Catabasis Pharmaceuticals,Inc.Files An 8-K Other Events
Item 8.01. Other Events.

Catabasis Pharmaceuticals, Inc. (the “Company”) is making publicly available an updated corporate slide presentation, which is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The updates focus on the functional improvements in boys receiving edasalonexent in the Company’s Phase 2 MoveDMD trial. The Company believes that these functional improvements constitute important information for a Phase 3 clinical trial plan for edasalonexent in Duchenne muscular dystrophy, which the Company expects to announce in the second half of 2017.

Item 9.01.  Financial Statements and Exhibits.

(d) Exhibits

The Exhibit to this Current Report on Form 8-K is listed in the Exhibit Index attached hereto.

Cautionary Note Regarding Forward-Looking Statements

This Current Report on Form 8-K, including the corporate slide presentation filed as Exhibit 99.1 hereto, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this Current Report on Form 8-K, including statements regarding the Company’s expectation of announcing a Phase 3 clinical trial plan for edasalonexent in Duchenne muscular dystrophy in the second half of 2017, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of important risks and uncertainties, including those described in the cautionary statements included in the Company’s most recent Quarterly Report on Form 10-Q, particularly in the “Risk Factors” section, which is on file with the Securities and Exchange Commission. Except as otherwise required by law, the Company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this Current Report on Form 8-K.




CATABASIS PHARMACEUTICALS INC Exhibit
EX-99.1 2 a17-15370_1ex99d1.htm EX-99.1 Exhibit 99.1 Catabasis Pharmaceuticals Corporate Update June 19,…
To view the full exhibit click here

An ad to help with our costs